Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antimalarial Drugs (; (2018) Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet (London, England), 391 (10128). pp. 1378-1390. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(18)30291-5

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S0140-6736(18)30291-5

Abstract

Item Type Article
PubMed ID 29606364

Share

Download

Filename: 1-s2.0-S0140673618302915-main.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar